Management and mechanisms of eosinophil action in asthma: mind the gap?
Russell REK., (2025), The Lancet. Respiratory medicine, 13, 190 - 191
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.
Ramakrishnan S. et al, (2025), The Lancet. Respiratory medicine, 13, 59 - 68
CORRECTION to: “Global mortality and readmission rates following COPD exacerbation-related hospitalisation: a meta-analysis of 65 945 individual patients” (ERJ Open Res 2024; 10: 00838-2023)
Waeijen-Smit K. et al, (2024), ERJ Open Research, 10
Clinical characteristics of chronic obstructive pulmonary disease patients with superoptimal peak inspiratory flow rate.
Kim T. et al, (2024), Scientific reports, 14
QRISK3 underestimates the risk of cardiovascular events in patients with COPD.
Amegadzie JE. et al, (2024), Thorax, 79, 718 - 724
Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19.
Cass SP. et al, (2024), ERJ open research, 10, 919 - 2023
Development and validation of a new algorithm for improved cardiovascular risk prediction
Hippisley-Cox J. et al, (2024), Nature Medicine, 30, 1440 - 1447
Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
Ramakrishnan S. et al, (2024), The Lancet. Respiratory medicine, 12, 67 - 77
Spirometry services in England post-pandemic and the potential role of AI support software: a qualitative study of challenges and opportunities
Doe G. et al, (2023), British Journal of General Practice, 73, e915 - e923
Inhaled corticosteroids for the treatment of COVID-19.
Bafadhel M. et al, (2022), European respiratory review : an official journal of the European Respiratory Society, 31
Moving the pathway goalposts: COPD as an immune-mediated inflammatory disease.
Cass SP. et al, (2022), The Lancet. Respiratory medicine, 10, 1110 - 1113
Performance of cough monitoring by Albus Home, a contactless and automated system for nocturnal respiratory monitoring at home
Do W. et al, (2022), ERJ Open Research, 8, 00265 - 2022
Performance of Contactless Respiratory Rate Monitoring by Albus HomeTM, an Automated System for Nocturnal Monitoring at Home: A Validation Study
Do W. et al, (2022), Sensors, 22, 7142 - 7142
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis
Baker JR. et al, (2022), The Lancet Respiratory Medicine, 10, 545 - 556
Discordant diagnostic criteria for pneumonia in COPD trials: a review
Wise RA. et al, (2021), European Respiratory Review, 30, 210124 - 210124
A new piece in the puzzle: the eosinophil and the development of COPD
Petousi N. et al, (2021), European Respiratory Journal, 58, 2101105 - 2101105
Renaming COPD exacerbations: the UK respiratory nursing perspective.
Mwasuku C. et al, (2021), BMC pulmonary medicine, 21
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Yu L-M. et al, (2021), The Lancet, 398, 843 - 855